Nath Bio-Genes

Why is Nath Bio-Genes (India) Ltd falling/rising?

As of 08-Aug, Nath Bio-Genes (India) Ltd's stock price is Rs 158.80, down 1.85%, reflecting a consistent downward trend with significant declines over various time frames and underperformance compared to the benchmark Sensex. Despite increased investor participation, the stock remains below its moving averages, indicating a bearish outlook.

As of 08-Aug, Nath Bio-Genes (India) Ltd is experiencing a decline in its stock price, currently at Rs 158.80, which reflects a decrease of Rs 3.0 or 1.85%. The stock has underperformed compared to the sector, with a performance today that is down by 1.82%. Additionally, the stock has been on a consecutive fall for the last two days, resulting in a total decline of 3.99% during this period.<BR><BR>The stock's performance over various time frames indicates a consistent downward trend, with a 1-week change of -0.22%, a 1-month change of -5.45%, and a 1-year decline of -8.97%. Over the longer term, the stock has significantly underperformed the benchmark Sensex, with a 3-year decline of -31.99% compared to a 19.02% increase in the Sensex, and a staggering 5-year decline of -58.22% against a 44.63% rise in the benchmark.<BR><BR>Moreover, Nath Bio-Genes is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically indicates a bearish trend. Although there has been a rise in investor participation, with delivery volume increasing by 25.73% against the 5-day average, this has not been sufficient to counteract the overall negative sentiment surrounding the stock. The stock also touched an intraday low of Rs 157.5, further highlighting the downward pressure on its price.

Which are the latest news on Nath Bio-Genes?

Are Nath Bio-Genes (India) Ltd latest results good or bad?

Nath Bio-Genes (India) Ltd's latest Q1 FY27 results show strong year-on-year growth in net profit (14.07%) and net sales (15.76%), but concerns about declining profit margins and low return on equity suggest potential sustainability issues, making it a cautious investment choice.

Nath Bio-Genes (India) Ltd's latest results for Q1 FY27 show a mixed performance. On the positive side, the company reported a net profit of ₹32.26 crore, which is a significant increase of 14.07% year-on-year. Additionally, net sales reached ₹328.40 crore, reflecting a year-on-year growth of 15.76%. This indicates that the company is benefiting from its peak season in the agricultural sector, traditionally its strongest quarter.<BR><BR>However, there are concerns regarding the sustainability of this performance. The profit margin (PAT margin) slightly decreased to 9.82% from 9.97% in the same quarter last year, suggesting that while revenue is growing, it is not translating into proportionate profit growth. Furthermore, the company's return on equity (ROE) remains low at 5.71%, indicating inefficiencies in capital utilization.<BR><BR>The volatility in earnings is also a critical factor, with a dramatic quarter-on-quarter swing from a marginal loss in Q4 FY26 to the current profit. This highlights the cyclical nature of the business, raising questions about its ability to maintain profitability in the upcoming weaker quarters.<BR><BR>Overall, while the results show strong growth in sales and profit for the quarter, the underlying issues with capital efficiency and earnings volatility suggest caution for investors. The company is currently viewed as a potential value trap, with attractive valuation multiples overshadowed by persistent quality concerns.

Should I buy, sell or hold Nath Bio-Genes (India) Ltd?

How big is Nath Bio-Genes?

As of 10th June, Nath Bio-Genes (India) Ltd has a market capitalization of 320.00 Cr, classifying it as a Micro Cap company, with net sales of 445.10 Cr and a net profit of 43.69 Cr reported in the latest four quarters. Specific values for Shareholder's Funds and Total Assets are not available.

As of 10th June, Nath Bio-Genes (India) Ltd has a market capitalization of 320.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Nath Bio-Genes reported net sales of 445.10 Cr and a net profit of 43.69 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period. However, specific values for Shareholder's Funds and Total Assets are not available.

Who are in the management team of Nath Bio-Genes?

The management team of Nath Bio-Genes includes Satish Kagliwal (Managing Director), Dhiraj Rathi (Company Secretary), Jeevanlata Kagliwal, Akash Nandkishor Kagliwal (Directors), and several Independent Directors: Ashu Jain, Vadla Nagbhushanam, Madhukar Deshpande, and Hitesh Rajnikant Purohit. They oversee the company's operations and strategic direction.

The management team of Nath Bio-Genes includes the following individuals:<BR><BR>1. **Satish Kagliwal** - Managing Director<BR>2. **Dhiraj Rathi** - Company Secretary & Compliance Officer<BR>3. **Jeevanlata Kagliwal** - Director<BR>4. **Ashu Jain** - Independent Director<BR>5. **Vadla Nagbhushanam** - Independent Director<BR>6. **Madhukar Deshpande** - Independent Director<BR>7. **Hitesh Rajnikant Purohit** - Independent Director<BR>8. **Akash Nandkishor Kagliwal** - Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the peers of the Nath Bio-Genes?

Nath Bio-Genes' peers include Sukhjit Starch, Sarveshwar Foods, Sayaji Industries, Prime Fresh, Aelea Commodities, Halder Venture, Tierra Agrotech, KN Agri Resource, and Sawaliya Food. In terms of management risk, growth, and capital structure, Nath Bio-Genes is rated below average in management risk and growth, with a good capital structure, and has a 1-year return of -17.29%.

Peers: The peers of Nath Bio-Genes are Sukhjit Starch, Sarveshwar Foods, Sayaji Industr, Prime Fresh, Aelea Commoditi., Halder Venture, Tierra Agrotech, KN Agri Resource, and Sawaliya Food.<BR><BR>Quality Snapshot: Excellent management risk is observed at Prime Fresh and Aelea Commoditi., while Good management risk is found at Sawaliya Food. Average management risk is present at Sukhjit Starch and Halder Venture, while Below Average management risk is noted at Sarveshwar Foods, Sayaji Industr, Nath Bio-Genes, Tierra Agrotech, and KN Agri Resource. Growth is Excellent at Aelea Commoditi. and Sawaliya Food, Good at Sarveshwar Foods and Prime Fresh, and Below Average at Sukhjit Starch, Sayaji Industr, Nath Bio-Genes, Halder Venture, Tierra Agrotech, and KN Agri Resource. Capital Structure is Excellent at Prime Fresh, Good at Nath Bio-Genes, Aelea Commoditi., and KN Agri Resource, Average at Sukhjit Starch, and Below Average at Sarveshwar Foods, Sayaji Industr, Halder Venture, and Tierra Agrotech.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Halder Venture at 227.86%, while Sarveshwar Foods has the lowest at -54.78%. Nath Bio-Genes has a 1-year return of -17.29%, which is higher than Sarveshwar Foods but lower than Halder Venture. Additionally, peers with negative six-month returns include Sarveshwar Foods, Aelea Commoditi., Halder Venture, Tierra Agrotech, and Sawaliya Food.

What does Nath Bio-Genes do?

Nath Bio-Genes (India) Ltd is a micro-cap company in the agricultural products sector, specializing in seed production and biotechnology. As of March 2026, it reported net sales of ₹52 Cr and a market cap of ₹320 Cr.

Overview:<BR>Nath Bio-Genes (India) Ltd operates in the Other Agricultural Products industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1993 as 'Shivnath Farms Private Limited', converted to a Public Limited Company on 13 September 2000 under the name 'Shivnath Farms Limited', and subsequently changed its name to Nath Bio-Genes (India) Limited on March 5, 2001. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 52 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 0 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 320 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 8.00<BR>- Industry P/E: 14<BR>- Dividend Yield: 1.19%<BR>- Debt Equity: 0.09<BR>- Return on Equity: 5.71%<BR>- Price to Book: 0.47<BR><BR>Contact Details:<BR>Address: Nath House Nath Road, P B No 318 Aurangabad, Maharashtra: 431005 <BR>Tel: 91-240-2376314 <BR>Email: investor@nathbiogens.com <BR>Website: http://www.nathbiogenes.com

How has been the historical performance of Nath Bio-Genes?

Nath Bio-Genes has shown consistent growth in net sales and profitability over the past four years, with net sales increasing from 278.36 crore in March 2022 to 364.91 crore in March 2025, and profit before tax improving from a loss of 63.43 crore to a profit of 40.04 crore in the same period. The company has demonstrated resilience, with positive earnings per share rising from -35.46 to 20.32.

Answer:<BR>The historical performance of Nath Bio-Genes shows a consistent growth trend in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Nath Bio-Genes has demonstrated a steady increase in net sales, rising from 278.36 crore in March 2022 to 364.91 crore in March 2025. Total operating income followed the same upward trajectory, reaching 364.91 crore in March 2025. The company's total expenditure, excluding depreciation, also increased, amounting to 315.11 crore in March 2025, up from 241.18 crore in March 2022. Operating profit, excluding other income, remained relatively stable, with a slight decrease to 49.80 crore in March 2025 from 49.86 crore in March 2024, while the overall operating profit (PBDIT) increased to 54.35 crore in March 2025. Profit before tax improved significantly from a loss of 63.43 crore in March 2022 to a profit of 40.04 crore in March 2025. Profit after tax also saw a positive trend, moving from a loss of 67.39 crore in March 2022 to a profit of 38.06 crore in March 2025. The earnings per share (EPS) reflected this growth, with values increasing from -35.46 in March 2022 to 20.32 in March 2025. Cash flow from operating activities was 17.00 crore in March 2025, down from 74.00 crore in March 2024, but the net cash inflow remained positive at 11.00 crore in March 2025, indicating a healthy liquidity position. Overall, Nath Bio-Genes has shown resilience and growth in its financial performance over the years.

When is the next results date for Nath Bio-Genes?

The next results date for Nath Bio-Genes is 13 November 2025.

The next results date for Nath Bio-Genes is scheduled for 13 November 2025.

Who are the top shareholders of the Nath Bio-Genes?

The top shareholders of Nath Bio-Genes include Ashu Farms LLP with 13.68% and Mayo Farms LLP with 5.72%. Individual investors hold 31.94%, while mutual funds have 3.89% and foreign institutional investors hold 0.21%.

The top shareholders of Nath Bio-Genes include Ashu Farms LLP, which holds the highest promoter stake at 13.68%. Additionally, Mayo Farms LLP is the largest public shareholder with a holding of 5.72%. The company also has significant individual investor holdings, accounting for 31.94%. In terms of institutional investment, mutual funds hold 3.89% across nine schemes, while foreign institutional investors (FIIs) have a minor stake of 0.21% through four FIIs. It's worth noting that there is a pledged promoter holding of 16.3764%.

Is Nath Bio-Genes overvalued or undervalued?

As of August 16, 2022, Nath Bio-Genes is considered very attractive and undervalued with a PE ratio of 9.43, significantly lower than its peers, while Kaveri Seed Co. is seen as expensive at a PE of 26.14, and despite its recent stock performance lagging behind the Sensex, its PEG ratio of 0.00 highlights strong growth potential.

As of 16 August 2022, the valuation grade for Nath Bio-Genes moved from attractive to very attractive, indicating a strong improvement in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.43, a price to book value of 0.56, and an EV to EBITDA of 7.98. These ratios suggest that Nath Bio-Genes is trading at a significant discount compared to its peers.<BR><BR>In comparison to its industry, Kaveri Seed Co. is deemed expensive with a PE ratio of 26.14, while MANGALAM SEEDS is classified as very attractive with a PE ratio of 19.17. The PEG ratio for Nath Bio-Genes stands at 0.00, further emphasizing its undervaluation relative to growth expectations. Notably, the company's recent stock performance has lagged behind the Sensex, particularly over the 3-year and 5-year periods, which may reflect market sentiment rather than its fundamental value.

What is the technical trend for Nath Bio-Genes?

As of May 27, 2025, Nath Bio-Genes shows a mildly bearish trend primarily due to daily moving averages, despite some conflicting signals from weekly and monthly indicators.

As of 27 May 2025, the technical trend for Nath Bio-Genes has changed from sideways to mildly bearish. The daily moving averages indicate a mildly bearish stance, while the weekly MACD and Bollinger Bands show mild bullishness, contrasting with the monthly bearish signals from both. The KST is bullish on the weekly but bearish monthly, and the Dow Theory reflects a mildly bullish trend on the weekly with no trend monthly. Overall, the current technical stance is mildly bearish, driven primarily by the daily moving averages and the monthly bearish indicators.

Has Nath Bio-Genes declared dividend?

Yes, Nath Bio-Genes (India) Ltd has declared a 20% dividend, amounting to ₹2 per share, with an ex-date of August 9, 2024. While recent price returns show volatility, the dividend contributes positively to total returns, especially over longer periods.

Nath Bio-Genes (India) Ltd has declared a 20% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 20%<BR>- Amount per share: 2<BR>- Ex-date: 09 Aug 24<BR><BR>Dividend Yield: 1.04%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -2.86%, the dividend return was 0%, resulting in a total return of -2.86%.<BR><BR>Over the past year, the price return was 0.96%, the dividend return was 0.98%, leading to a total return of 1.94%.<BR><BR>In the 2-year period, the price return was -0.31%, the dividend return was 2.10%, which resulted in a total return of 1.79%.<BR><BR>For the 3-year period, the price return was 4.37%, the dividend return was 3.82%, yielding a total return of 8.19%.<BR><BR>In the last 4 years, the price return was -54.81%, with a dividend return of 2.09%, culminating in a total return of -52.72%.<BR><BR>Over the 5-year period, the price return was -41.79%, the dividend return was 2.52%, resulting in a total return of -39.27%.<BR><BR>Overall, Nath Bio-Genes has declared a dividend, which contributes positively to the total returns, especially in the longer term. However, the recent price returns indicate some volatility, particularly over the past few years.